The Future Of Drug Discovery Is 4 Billion Years Old (Viswa Colluru, Founder & CEO at Enveda)

2026-06-02 · Source: The Generalist · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Medical Devices & Health Technology · Depth: Intermediate, extended

Summary

Enveda Biosciences, founded by Viswa Colluru, is revolutionizing drug discovery by leveraging AI to explore nature's chemistry, a field largely abandoned by the pharmaceutical industry. Since its 2019 inception, Enveda has secured over \$500 million and identified 18 drug candidates, with three currently in clinical trials. This approach, inspired by Colluru's personal experience with his mother's leukemia and the high cost of Gleevec, aims to find potent medicines from natural sources, which historically account for a third of all FDA-approved drugs. Enveda's method is notably efficient, developing candidates approximately four times faster and ten times cheaper, at around \$1 million each. Its leading programs include a Phase 2 oral treatment for eczema, a Phase 1 oral obesity drug targeting the leptin system, and a Phase 1 oral treatment for ulcerative colitis, all demonstrating promising efficacy and safety profiles. The company envisions becoming an integrated pharmaceutical entity, bringing first-in-class medicines to market within this decade.

Key takeaway

For Directors of AI/ML in pharmaceutical R&D or entrepreneurs evaluating biotech opportunities, you should reconsider traditional drug discovery paradigms. Enveda's success demonstrates that AI-driven exploration of natural product chemistry can yield first-in-class medicines faster and cheaper than synthetic approaches. Prioritize platforms that systematically decode nature's vast, evolutionarily optimized chemical library, especially for chronic diseases where oral, safe, and convenient treatments are lacking. Your investment in such overlooked areas could unlock significant market value and address unmet patient needs.

Key insights

AI-driven exploration of nature's chemistry offers a potent, overlooked pathway for discovering first-in-class, affordable medicines.

Principles

• Old ideas often precede major inflections.
• Nature's chemistry is a deeply evolutionarily selected pool.
• Chemistry can teach us biology, not just vice-versa.

Method

Enveda employs AI to build a "sequencer for life's chemistry," identifying the structure and function of molecules in plants. It targets plants used across cultures for similar symptoms, then isolates single active compounds for drug development.

In practice

• Target plants used across diverse cultures for similar symptoms.
• Benchmark new compounds against existing medicines in mouse models.
• Focus on developing oral, once-daily medicines for chronic diseases.

Topics

• Natural Product Drug Discovery
• AI-driven Drug Discovery
• Enveda Biosciences
• Chronic Disease Therapies
• Computational Metabolomics
• Pharmaceutical Innovation

Best for: Investor, AI Scientist, Entrepreneur, Director of AI/ML

Related on AIssential

• Demis Hassabis On What AI Will Do Next — AI is evolving into a co-creative partner, poised to accelerate scientific discovery and revolutionize human health within decades.
• Pretraining a foundation model for small-molecule natural products — NaFM is a foundation model for natural products, outperforming existing methods in drug discovery tasks.
• 😺 🎙️ Watch: How Isomorphic Labs works to drug "undruggable" diseases — AI, particularly AlphaFold-derived technology, is dramatically accelerating drug discovery and tackling previously "undruggable" targets.
• NVIDIA & Eli Lilly: The AI Revolution in Drug Discovery | Jensen Huang & David Ricks — Co-designing computing stacks for specific problems accelerates applications far beyond Moore's Law.
• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• He Raised $70M to Cure Every Disease With AI — AI agents, particularly specialized models, significantly accelerate scientific discovery by removing human talent bottlenecks and enabling high-throughput reasoning.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The Generalist.